Industry Symposium with ACPE Credit and Breakfast
Treatment Advancements to Overcome Barriers in the Management of Schizophrenia: Key Considerations for Pharmacists
Supported by Alkermes

Registration Options

Activity Date: 04/26/2022

Session Time and Location

Session Summary

The presentation will begin after in-person meals are served (an estimated 15-30 minute delay). Thank you for your patience.

Clinical consequences associated with uncontrolled symptoms of schizophrenia present treatment challenges and can increase disease burden for both patients and health care providers. Recognizing treatment challenges, including nonadherence to therapy or suboptimal therapy, and identifying potential strategies to improve adherence are essential to prevent disease relapse and improve overall patient outcomes. Pharmacists have an important role in the treatment of schizophrenia by helping to choose initial therapy according to patient-specific factors, addressing suboptimal therapeutic responses, and mitigating adverse effects. The current treatment landscape of schizophrenia continues to evolve with novel therapies and routes of administration, offering pharmacists more opportunities to make treatment interventions to improve patients’ symptom control, improve adherence, and address treatment-related challenges. This program will review updated clinical guidelines, efficacy and safety of newer treatment strategies, and considerations for their administration in both inpatient and outpatient clinical practice settings.

HOW TO RECEIVE CREDIT

Please follow the below instructions to claim your credit:

• Go to: https://www.pharmacytimes.org/cpnp22-eval
  • To continue, you will need to be logged into your PTCE account.
  • If you do not have a PTCE account, create one using the prompt on the page.
• Once logged in, answer the activity evaluation, and click ‘Complete Survey’.
• After completing the survey, click the blue arrow button to complete the activity and request credit.
• Your credit will be uploaded to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net

NOTE: Participation data will not be uploaded into CPE Monitor if you do not have your NABP (e-profile ID) number and date of birth entered in your profile.

All participants must request credit by July 26, 2022.

Faculty Information and Disclosures

Learning Objectives

• Explore the current and emerging data on the disease burden and progression of schizophrenia
• Discuss current evidence-based guidelines, newly emerging agents, and therapeutic challenges in schizophrenia
• Highlight the role of the pharmacist in addressing treatment challenges in schizophrenia, including patient education and optimizing adherence

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

Grant Support